We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Neuropharm | LSE:NPH | London | Ordinary Share | GB00B1NPJJ01 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.50 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMNPH
RNS Number : 9619J
Neuropharm Group PLC
09 April 2010
+-------------------------------+-------------------------------+
| For Immediate Release | 9 April 2010 |
+-------------------------------+-------------------------------+
Neuropharm Group Plc
("Neuropharm" or "the Company")
Board Change
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on
neurodevelopmental disorders, announces that Dr Mike Snape is stepping down from
his position as Chief Scientific Officer and from the board of the Neuropharm
Group with effect from 9th April. The Board would like to thank Dr Snape for
his considerable contribution as a founder of the Company and Chief Scientific
Officer since its inception in 2005.
For further information please contact:
+----------------------------------------+--------------------------+
| Neuropharm | + 44 (0) 1372 371 171 |
+----------------------------------------+--------------------------+
| Robert Mansfield, Chief Executive | |
| Officer | |
| Graham Yeatman, Chief Financial | |
| Officer | |
+----------------------------------------+--------------------------+
| | |
+----------------------------------------+--------------------------+
| Piper Jaffray Ltd. | + 44 (0) 20 3142 8700 |
+----------------------------------------+--------------------------+
| Neil Mackison, Rupert Winckler | |
+----------------------------------------+--------------------------+
| | |
+----------------------------------------+--------------------------+
| Buchanan Communications | + 44 (0) 20 7466 5000 |
+----------------------------------------+--------------------------+
| Mark Court | |
+----------------------------------------+--------------------------+
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of
medicines for the treatment and management of neurodevelopmental disorders.
Please visit www.neuropharm.co.uk for further information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAKKCDQKBKDFQK
1 Year Neuropharm Chart |
1 Month Neuropharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
